Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes

Lam, Xanthe M.; Duenas, Eileen; Daugherty, Ann L.; Levin, Nancy; Cleland, Jeffrey L.

doi:10.1016/s0168-3659(00)00224-8

Cited by 125 publications

(82 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the mean lifetime of the sites depends on these initial assumptions and corresponding model choices. The release profiles obtained correspond to typical experimental profiles of release of macromolecules from PLGA spheres [9,10]. In all cases, a short initial burst was observed, corresponding to the release of the particles situated on the surface of the sphere.…”

Section: Effect Of Erosion Ratesupporting

confidence: 67%

“…Experimental work has shown that an increase in drug loading results in a corresponding increase in the release rate [9,10]. Sandor et al have measured the protein loadings, as a percentage of the total weight of the nanospheres.…”

Section: Effect Of the Distribution Of Drug Particles In The Spherementioning

confidence: 99%

“…Besides the fact that it is non-toxic (PLGA nanospheres can be 16 times more effective for cell viability than the free drug, [5]), this material has proved capable of easy encapsulation [5] and subsequent release of drug (especially of pharmaceutically active proteins), in a sustained manner. Experimental studies such as [5,9,10] demonstrate the potential for encapsulation and sustained release of a wide variety of proteins from PLGA spheres.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Quantitative multi-agent models for simulating protein release from PLGA bioerodible nano- and microspheres

Barat

Crane

Ruskin

2008

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Summary. Using poly(lactide-co-glycolide) (PLGA) particles for drug encapsulation and delivery has recently gained considerable popularity for a number of reasons. An advantage in one sense, but a drawback of PLGA use in another, is that drug delivery systems made of this material can provide a wide range of dissolution profiles, due to their internal structure and properties related to particles' manufacture. The advantages of enriching particulate drug design experimentation with computer models, are evident with simulations used to predict and optimize design, as well as indicate choice of best manufacturing parameters. In the present work, we seek to understand the phenomena observed for PLGA micro-and nanospheres, through Cellular Automata (CA) agent-based Monte Carlo (MC) models. Systems are studied both over large temporal scales, (capturing slow erosion of PLGA) and for various spatial configurations (capturing initial as well as dynamic morphology). The major strength of this multi-agent approach is to observe dissolution directly, by monitoring the emergent behaviour: the dissolution profile manifested, as a sphere erodes. Different problematic aspects of the modelling process are discussed in details in this paper. The models were tested on experimental data from literature, demonstrating very good performance. Quantitative discussion is provided throughout the text in order to make a demonstration of the use in practice of the proposed model.

show abstract

Section: Effect Of Erosion Ratesupporting

confidence: 67%

Section: Effect Of the Distribution Of Drug Particles In The Spherementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative multi-agent models for simulating protein release from PLGA bioerodible nano- and microspheres

Barat

Crane

Ruskin

2008

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

show abstract

“…However, expectations concerning the delivery of therapeutic proteins have been limited by their fragile structure and the frequent administrations required (Yang et al, 1997;Lam et al, 2000;Sinha et al, 2003). To protect them from proteolysis, to allow for their sustained delivery and to enhance their therapeutic efficacy, their encapsulation in injectable, biodegradable microparticles has been explored (Pean et al, 1999;Rosa et al, 2000;Aubert-Pouessel et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

How to achieve sustained and complete protein release from PLGA-based microparticles?

Giteau

Venier-Julienne

Aubert-Pouëssel

et al. 2008

International Journal of Pharmaceutics

235

184

View full text Add to dashboard Cite

One of the most challenging tasks in the delivery of therapeutic proteins from PLGAbased microparticles is the sustained and complete release of the protein in its native form.The mechanisms responsible for incomplete protein release from these devices are numerous and complex; the beneficial effect of different formulations has often been evaluated in vitro.Strategies employed for overcoming protein destabilization during the release step are reviewed in this paper. Proteins have been protected in the deleterious environment by adding stabilizers to the formulation, or by modifying the protein or the polymer. Alternatively, some strategies have aimed at avoiding the formation of the destabilizing environment. As experimental conditions may influence the results from in vitro release studies, we initially report precautions to avoid adverse effects.

show abstract

“…We have previously shown that proteins encapsulated under a nanosolid state within a PLGA polymer preserve their structure and integrity, allowing a better and prolonged release profile and the maintenance of their biological activity . In order to optimize the preparation of small peptides, various methods like spraydrying or spray-freeze drying have been reported (Lam et al, 2000;Wang et al, 2004). Even 380 if these methods can generate protein particles, they have several disadvantages, such as the complexity of the technique, leading to low protein recovery and, above all, they may denature proteins.…”

Section: Discussionmentioning

confidence: 99%

Nanoprecipitated catestatin released from pharmacologically active microcarriers (PAMs) exerts pro-survival effects on MSC

Angotti

Venier-Julienne

Penna

et al. 2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Catestatin (CST), a fragment of Chromogranin-A, exerts angiogenic, arteriogenic, vasculogenic and cardioprotective effects. CST is a very promising agent for revascularization purposes, in "NO-OPTION" patients. However, peptides have a very short half-life after administration and must be conveniently protected. Fibronectin-coated 30 pharmacologically active microcarriers (FN-PAM), are biodegradable and biocompatible polymeric microspheres that can convey mesenchymal stem cell (MSCs) and therapeutic proteins delivered in a prolonged manner. In this study, we first evaluated whether a small peptide such as CST could be nanoprecipitated and incorporated within FN-PAMs.

show abstract

Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes

Cited by 125 publications

References 19 publications

Quantitative multi-agent models for simulating protein release from PLGA bioerodible nano- and microspheres

Quantitative multi-agent models for simulating protein release from PLGA bioerodible nano- and microspheres

How to achieve sustained and complete protein release from PLGA-based microparticles?

Nanoprecipitated catestatin released from pharmacologically active microcarriers (PAMs) exerts pro-survival effects on MSC

Contact Info

Product

Resources

About